ArticlePloS one2020
Clinical implications of elevated serum interleukin-6 in IgG4-related disease.
Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 15 citations in OpenAlex.
- Implementing AI-enabled chest X-ray for community-based integrated screening for tuberculosis, chronic respiratory diseases, and cardiovascular diseases in Nigeria.BMC global and public health · 2026Article
- Clinical significance of serum IgE levels in IgG4-related ophthalmic disease: a single-centre study.Eye (London, England) · 2026Article
- Tocilizumab in the treatment of IgG4-related disease involving the carotid artery-case report and literature review.Frontiers in immunology · 2026Review
- Comparison of IgG4 with inflammatory cytokines (IL-1, IL-6 and TNFα) in rheumatoid arthritis.Frontiers in immunology · 2025Article
- Immune cell crosstalk between ANCA-associated vasculitis and IgG4-related disease: an unresolved pathogenic link.Frontiers in immunology · 2025Review
- Unmet needs in biomarkers for autoimmune pancreatitis diagnosis.World journal of gastroenterology · 2024Article
- Long-term Outcomes after Steroid Pulse Therapy in Patients with Type 1 Autoimmune Pancreatitis.Internal medicine (Tokyo, Japan) · 2023Article
- Primary sclerosing encapsulating peritonitis: a case report.Journal of medical case reports · 2023Article
- Correlation between serologic parameters and disease activity of IgG4-related disease: Differences between patients with normal and elevated serum IgG4 concentrations.Frontiers in immunology · 2022Article
- Management of retroperitoneal fibrosis with endovascular aneurysm repair in patients refractory to medical management.Frontiers in surgery · 2022Article
- An Autopsy Case of Multicentric Castleman Disease Presenting with Severe Jaundice.Internal medicine (Tokyo, Japan) · 2021Article
- IL-6 expression helps distinguish Castleman's disease from IgG4-related disease in the lung.BMC pulmonary medicine · 2021Article
- Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease.World journal of gastroenterology · 2021Article
- Identification of serum IFN-α and IL-33 as novel biomarkers for type 1 autoimmune pancreatitis and IgG4-related disease.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSome patients with IgG4-related disease (IgG4-RD) exhibit elevated serum interleukin (IL)-6 with excessive inflammatory reactions or with repeating relapse. To date few reports pertaining to clinical implications of elevated serum IL-6 in IgG4-RD patients have been published. The aims of the current retrospective study were to investigate the clinical implications of elevated serum IL-6 in IgG4-RD patients, and to examine whether IL-6 can predict the activity and/or relapse of the disease. MATERIALS AND
methodsWe examined the clinical picture at the onset of 43 patients who were diagnosed with IgG4-RD in our hospital and were able to measure serum IL-6 before steroid treatment.
resultsThe median level of serum IL-6 was 2.2 pg/mL. There was a significant correlation between IL-6 and C-reactive protein (CRP) level (r = 0.397, p = 0.008), hemoglobin level (r = -0.390, p = 0.010) and albumin level (r = -0.556, p < 0.001). When 43 patients were divided into two groups by using a cut-off IL-6 of 4 pg/mL, the high IL-6 group showed higher age, lower albumin, higher CRP and higher aspartate aminotransferase (AST) (age p = 0.014, albumin p = 0.006, CRP p <0.001, AST p = 0.009). Hepatic swelling and splenomegaly were significantly more prevalent in the high IL-6 group than it was in the low IL-6 group (liver p < 0.001, spleen p = 0.020). Biliary tract involvement tended to admit more in the high IL-6 group (p = 0.060).
conclusionSerum IL-6 level at the onset of IgG4-RD may be significantly correlated with clinical inflammatory parameters and it may also be associated with involvement of the bile duct, liver, and spleen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.